Redx Pharma PLC (LON:REDX) rose 11.1% on Tuesday . The company traded as high as GBX 7.90 ($0.10) and last traded at GBX 7.50 ($0.10). Approximately 183,829 shares traded hands during mid-day trading, an increase of 171% from the average daily volume of 67,755 shares. The stock had previously closed at GBX 6.75 ($0.09).
Redx Pharma (LON:REDX) last issued its quarterly earnings data on Monday, November 19th. The company reported GBX (7) (($0.09)) earnings per share for the quarter, missing the Zacks’ consensus estimate of GBX (6.50) (($0.08)) by GBX (0.50) (($0.01)).
WARNING: This piece was originally posted by Week Herald and is owned by of Week Herald. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://weekherald.com/2019/02/14/redx-pharma-redx-stock-price-up-11-1.html.
About Redx Pharma (LON:REDX)
Redx Pharma Plc operates as a drug discovery and development company in the United Kingdom. It discovers and develops small molecule drugs for treating cancer and fibrosis. The company is developing RXC004, a porcupine inhibitor for the treatment of pancreatic, biliary, and gastric cancers, as well as melanoma; ROCK inhibitor for treating inflammatory disease related fibrosis; ROCK2, a Rho-associated protein kinase 2 inhibitor for the treatment of diabetic nephropathy, and IPF and NASH/liver fibrosis; and Porcupine (RXC006), a drug for idiopathic pulmonary fibrosis (IPF), non-alcoholic steatohepatitis (NASH), and liver fibrosis.
Featured Story: What are the components of an earnings report?
Receive News & Ratings for Redx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.